To Bleed or Not to Bleed: Dual versus Triple Therapy in Patients with Acute Coronary Syndrome Atrial Fibrillation
The presentation will focus on evidence-based information regarding antithrombotic therapy in patients with acute coronary syndrome (ACS) and atrial fibrillation (AF). The presentation will also highlight current literature related to dual versus triple therapy. Exposure to patients receiving these therapies may differ between pharmacists, but it is imperative that all clinicians understand how to appropriately manage said patients. Consequently, the presentation will provide case-based application questions. As such, pharmacists who are familiar with this patient population and those who are not will gain knowledge that will enable them to provide safe and effective care. This presentation is a great importance to Slidell Memorial Hospital’s patients due to the majority of them being cardiac patients.
Target Audience
- Pharmacists
- Pharmacy technicians
Learning Objectives
Pharmacist learning objectives
- Describe the pathophysiology of AF and ACS.
- Differentiate the associated mechanism of action, warnings, adverse effects, and dose adjustments of antithrombotic agents.
- Distinguish appropriate therapy (dual vs. triple) for patients post-ACS with concomitant AF based on current evidence.
Pharmacy technician learning objectives
- Identify brand/generic name of the antithrombotic agents used in post-acute coronary syndrome (ACS) and atrial fibrillation.
- Recognize different dosage strengths of antithrombotic agents.
Additional Information
Attachment | Size |
---|---|
Helpful Tips for Users.pdf | 157.72 KB |
Information for CE Credit - To Bleed or Not to Bleed.docx | 125.27 KB |
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician